Analysis and Discussion of Deaths, Other Serious Adverse Events, and Other Significant Adverse Events in Clinical Study Report
ICH E3 section 12.3.3 calls for analysis and discussion across deaths, other serious adverse events, and other significant adverse events after the relevant case listings and narratives. This is an interpretive synthesis, not a duplicate death/serious-event listing or a replacement for individual patient narratives.
ReviewedEvidence1 sourceSectionWriting & Style
Quick answer
This subsection synthesizes clinically important case patterns, treatment relationships, timing, and other evidence needed to interpret the study’s most consequential safety events.
Key details
Core IssueICH E3 section 12.3.3 calls for analysis and discussion across deaths, other serious adverse events, and other significant adverse events after the relevant case listings and narratives.
Registerscholarly, professional, or research/report writing
Important caveats
Scope Boundary
This is an interpretive synthesis, not a duplicate death/serious-event listing or a replacement for individual patient narratives.
Further guidance
Content
Discuss cross-case patterns and plausible study-treatment relationships using the underlying listings, narratives, exposure, and clinical context without losing patient traceability.
Purpose
This subsection synthesizes clinically important case patterns, treatment relationships, timing, and other evidence needed to interpret the study’s most consequential safety events.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
ICH E3 section 12.2.3 calls for analysis of adverse events beyond their tabular display, focusing on patterns important to safety interpretation. Do not treat the analysis as a substitute for the event display or patient-level listing, and do not imply causality beyond what the study evidence supports.
ICH E3 section 12.3.1.3 distinguishes other significant adverse events from deaths and other serious adverse events for focused safety reporting. Do not merge this category with all adverse events, deaths, or other serious adverse events; ICH E3 gives these safety groupings separate reporting roles.
ICH E3 section 12.2.1 calls for a brief summary of adverse events within the safety evaluation before more detailed displays and analyses. Keep this section a high-level summary; it is not a substitute for detailed adverse-event displays, patient-level listings, serious-event treatment, or narratives.
ICH E3 section 12.2.2 provides for structured display of adverse events as part of the clinical study report safety evaluation. A summary display is distinct from patient-level adverse-event listings and from narratives of selected serious or otherwise significant cases.
ICH E3 requires other serious adverse events to receive focused safety reporting, including patient-level listing and narrative treatment when needed to understand the event and its relationship to study treatment. ICH E3 distinguishes deaths from other serious adverse events for listing purposes; a fatal serious event may be referenced in both contexts, so counting and cross-references must remain clear.
ICH E3 Section 13 calls for a concise discussion of efficacy and safety results, the risk-benefit relationship, unexpected findings, clinical relevance, unresolved issues, and implications for future studies without merely repeating results or introducing new ones. This section interprets results already presented; it should not simply duplicate result tables and should not introduce new study results that were not reported elsewhere.
ICH E3 section 9.4.5 addresses rules or methods used to select the dose and timing of dose for individual patients. This is the patient-level dosing procedure subsection, not the preceding rationale for selecting the study doses or the later results analysis of dose-response relationships.
ICH E3 places patient-level adverse-event listings in the report appendices and calls for listings that identify individual patients and relevant event details supporting review. A listing is not the same as a summary adverse-event table or a selected patient narrative; each serves a different level of safety reporting.
